EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer

Margaret Ndinguri, Lisa Middleton, Jason Unrine, Shu Lui, Joseph Rollins, Emma Nienaber, Cassidy Spease, Aggie Williams, Lindsay Cormier iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0287151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Margaret Ndinguri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Eastern Kentucky University, Richmond, Kentucky, United States of America. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NHLBI NIH HHS, Kentucky IDeA Networks of Biomedical Research Excellence.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Pt-Mal-LHRH is a newly synthesized chemotherapeutic agent that was designed to selectively target the luteinizing hormone-releasing hormone (LHRH) receptor expressed by triple negative breast cancer (TNBC). The aim of this study was to evaluate the therapeutic dosing, tumor reduction efficacy, and selective distribution of Pt-Mal-LHRH in-vivo. Methods and results LHRH tissue expression levels in-vivo were investigated using western blotting and LHRH was found to be increased in reproductive tissues (mammary, ovary, uterus). Further, Pt-Mal-LHRH was found to have increased TNBC tumor tissue platinum accumulation compared to carboplatin by inductively coupled plasma mass spectrometry analysis. The platinum family, compound carboplatin, was selected for comparison due to its similar chemical structure and molar equivalent doses were evaluated. Moreover, in-vivo distribution data indicated selective targeting of Pt-Mal-LHRH by enhanced reproductive tissue accumulation compared to carboplatin. Further, TNBC tumor growth was found to be significantly attenuated by Pt-Mal-LHRH compared to carboplatin in both the 4T1 and MDA-MB-231 tumor models. There was a significant reduction in tumor volume in the 4T1 tumor across Pt-Mal-LHRH doses (2.5–20 mg/kg/wk) and in the MDA-MB-231 tumor at the dose of 10 mg/kg/wk in models conducted by an independent contract testing laboratory.

Conclusion

Our data indicates Pt-Mal-LHRH is a targeting chemotherapeutic agent towards the LHRH receptor and reduces TNBC tumor growth in-vivo. This study supports drug conjugation design models using the LHRH hormone for chemotherapeutic delivery as Pt-Mal-LHRH was found to be a more selective and efficacious than carboplatin. Further examination of Pt-Mal-LHRH is warranted for its clinical use in TNBCs, along with, other reproductive cancers overexpressing the LHRH receptor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAntineoplastic AgentsFemaleHumansReceptors, LHRHCarboplatinPlatinumGonadotropin-Releasing HormoneCell Line, Tumor

Substanzen

Receptors, LHRHCarboplatinPlatinumGonadotropin-Releasing HormoneAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Chemistry, Eastern Kentucky University, Richmond, Kentucky, United States of America.
  • Department of Biological Sciences, Eastern Kentucky University, Richmond, Kentucky, United States of America.
  • Department of Plant and Soil Sciences, University of Kentucky, Lexington, Kentucky, United States of America.
  • Department of Physiology, University of Kentucky, Lexington, Kentucky, United States of America.

ORCID-Profile: Lindsay Cormier

Förderung

  • NIGMS NIH HHS
  • NHLBI NIH HHS
  • Kentucky IDeA Networks of Biomedical Research Excellence
  • Foundation for the National Institutes of Health

Zitieren

APA

Ndinguri, M., Middleton, L., Unrine, J., Lui, S., Rollins, J., Nienaber, E., Spease, C., Williams, A., & Cormier, L. (2023). Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0287151

Vancouver

Ndinguri M, Middleton L, Unrine J, Lui S, Rollins J, Nienaber E, et al. Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer. PLOS ONE. 2023. doi:10.1371/journal.pone.0287151

BibTeX
@article{Ndinguri2023,
  author = {Ndinguri, Margaret and Middleton, Lisa and Unrine, Jason and Lui, Shu and Rollins, Joseph and Nienaber, Emma and Spease, Cassidy and Williams, Aggie and Cormier, Lindsay},
  title = {Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0287151}
}
Kostenlos starten →